Código QR (código de barras bidimensional)

Tislelizumab plus anlotinib with or without radiotherapy as first-line therapy in advanced hepatocellular carcinoma: a single center, non-randomized retrospective case–control study

Abstract The purpose of this study was to investigate the efficacy and safety of tislelizumab (monoclonal antibody) plus anlotinib (tyrosine kinase inhibitor) with or without radiotherapy in advanced hepatocellular carcinoma (HCC). Ninety patients with advanced HCC were divided into two groups: tisl...

Fuld beskrivelse

Na minha lista:
Principais autores: Guishu Wu, Yuhong Liu, Huaxi Fan, Mingyue Rao, Jing Zhang, Jianwen Zhang
Format: Artigo
Sprog:Inglês
Udgivet: Springer 2025-03-01
Serier:Discover Oncology
Fag:
Hepatocellular carcinoma
Immune checkpoint inhibitors
Immunotherapy
Targeted therapy
Radiotherapy
Online adgang:https://doi.org/10.1007/s12672-025-02171-5
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker